Healthcare and Medical

home | healthcare and medical | company profile

£265.00
Report Delivery: Via Email
Alerts
Change Currency EuroUSDGBP

Premium Company Profile Novavax (Datamonitor)

  • Market: Healthcare and Medical
  • Published Date: 31/10/2007
  • Report Title: Premium Company Profile Novavax
  • Table of Contents: View Table of Contents
  • Report Type: Company Profile
  • Country: Global
  • Number of Pages: 46
Introduction

Novavax is a biopharmaceutical company focused on developing vaccines against the H5N1, H9N2 and other subtypes of avian influenza with pandemic potential as well as vaccines that protect against seasonal influenza. These vaccines leverage the company's virus-like particle (VLP) platform technology, Novasome adjuvants and unique production technology.

Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


  • Highlights

    Novavax is focused on creating vaccines for a range of infectious diseases. The company's Estrasorb is the first topical emulsion for estrogen therapy approved by the FDA for the treatment of moderate to severe vasomotor symptoms associated with menopause. The company also markets Gynodiol used for estrogen replacement therapy.

    The company's total revenues declined at a CAGR of 25% during 2002-2006, from $15 million to $5 million. The major reason for revenue decline was the decreasing product sales. Product sales of the company decreased at a CAGR of 34% during 2002-2006, from $13 million to $3 million.

    The company's total revenues would increase at a CAGR of 12% during 2006-2010 from $5 million to $8 million. The company's biggest contributor to revenue growth out to 2010 will be revenues from contract research and development.

    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company's adjusted five year financial data along with key ratios and market capitalization
  • £265.00   Share Report
     
    Alerts  

    Purchase Information

    There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card ; Credit Card ; Purchase via Invoice (inc. Purchase Order no. if required) and Paypal. Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.

    Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.

    Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.

    Worldpay Logo
    Chancy Currency EUR USD GBP
    Customer Area
    English Italian Spanish French German Russian Chinese Arabic